
NIO is poised to release Q2 2025 earnings, with consensus estimating a $0.30 loss per share on $2.76 billion revenue, supported by a 25.6% year-over-year delivery increase to 72,056 units, primarily from its new ONVO and Firefly brands. Despite improving vehicle margins to 10.2%, significant SG&A expenses and a $3 billion net loss in 2024 raise concerns about its ambitious Q4 2025 breakeven target and overall profitability. While long-term catalysts like its extensive battery swap network exist, high debt and a history of missed earnings suggest new investors should exercise caution and await clearer financial improvements.
NIO is approaching its second-quarter 2025 earnings release with consensus estimates projecting a loss of $0.30 per share on $2.76 billion in revenue, indicating a 15% year-over-year revenue increase and a slight improvement from the year-ago loss of $0.34 per share. This top-line growth is underpinned by a 25.6% year-over-year increase in vehicle deliveries to 72,056 units. However, this growth is entirely driven by the new ONVO and Firefly sub-brands, as sales from the core NIO brand declined by approximately 18% from the same quarter in 2024. While vehicle margins showed improvement, rising to 10.2% in the first quarter, significant operational pressures persist. SG&A expenses grew 46.8% year-over-year in the last reported quarter, and this trend of high spending on marketing and network expansion is expected to continue, eroding profitability. The company's financial position is precarious, with a substantial $3 billion net loss in 2024 and a long-term debt-to-capital ratio of 0.76, well above the industry average of 0.28. Despite the stock's 50% rise over the past six months, outperforming peers, its path to its stated goal of breaking even in Q4 2025 appears ambitious given its history of missing EPS estimates and ongoing high cash burn.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
-0.15
Ticker Sentiment